{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:41:33Z","timestamp":1790847693721,"version":"4.1.0"},"reference-count":132,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"NIH","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"NIH","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"NIH","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"NIH","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"NIH","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"NIH","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"NIH","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"NIH","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"NIH","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"American Parkinson Disease Association, Parkinson\u2019s Foundation","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"Courtney Ann Diacont Memorial Foundation, and Targeted Diagnostic &amp; Therapeutics, Inc.","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"NIH\/NCI","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"NIH\/NCI","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"NIH\/NCI","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"NIH\/NCI","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"NIH\/NCI","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"NIH\/NCI","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"NIH\/NCI","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"NIH\/NCI","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"NIH\/NCI","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"NIH\/NCI","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"Kleberg Foundation (Medical Research Award)","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"David and Lorraine Swoyer","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"David and Lorraine Swoyer","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"David and Lorraine Swoyer","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"David and Lorraine Swoyer","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"David and Lorraine Swoyer","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"David and Lorraine Swoyer","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"David and Lorraine Swoyer","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"David and Lorraine Swoyer","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"David and Lorraine Swoyer","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"David and Lorraine Swoyer","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"pre-doctoral fellowship from the PhRMA Foundation","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R01 CA204881"],"award-info":[{"award-number":["1R01 CA204881"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R01 CA206026"],"award-info":[{"award-number":["1R01 CA206026"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R21 1NS130388"],"award-info":[{"award-number":["1R21 1NS130388"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R01 DK1388341"],"award-info":[{"award-number":["1R01 DK1388341"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["W81XWH-17-PRCRP-TTSA"],"award-info":[{"award-number":["W81XWH-17-PRCRP-TTSA"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["PF-IMP-1045175"],"award-info":[{"award-number":["PF-IMP-1045175"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["W81XWH-22-1-0207"],"award-info":[{"award-number":["W81XWH-22-1-0207"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R21 CA267087"],"award-info":[{"award-number":["1R21 CA267087"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["1R21 CA286339"],"award-info":[{"award-number":["1R21 CA286339"]}]},{"name":"NIH Ruth Kirschstein Individual Research Fellowship Award","award":["F30NS125921"],"award-info":[{"award-number":["F30NS125921"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Neurological disorders are the leading cause of cognitive and physical disability worldwide, affecting 15% of the global population. Due to the demographics of aging, the prevalence of neurological disorders, including neurodegenerative diseases, will double over the next two decades. Unfortunately, while available therapies provide symptomatic relief for cognitive and motor impairment, there is an urgent unmet need to develop disease-modifying therapies that slow the rate of pathological progression. In that context, biomarkers could identify at-risk and prodromal patients, monitor disease progression, track responses to therapy, and parse the causality of molecular events to identify novel targets for further clinical investigation. Thus, identifying biomarkers that discriminate between diseases and reflect specific stages of pathology would catalyze the discovery and development of therapeutic targets. This review will describe the prevalence, known mechanisms, ongoing or recently concluded therapeutic clinical trials, and biomarkers of three of the most prevalent neurodegenerative diseases, including Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson\u2019s disease (PD).<\/jats:p>","DOI":"10.3390\/biom14040398","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:34:58Z","timestamp":1711452898000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Biomarkers for Managing Neurodegenerative Diseases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-5957","authenticated-orcid":false,"given":"Lara","family":"Cheslow","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Department of Neurosciences, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-4560","authenticated-orcid":false,"given":"Adam E.","family":"Snook","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-175X","authenticated-orcid":false,"given":"Scott A.","family":"Waldman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Van Schependom, J., and D\u2019Haeseleer, M. (2023). Advances in Neurodegenerative Diseases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051709"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"ref_4","first-page":"111","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/mds.27090","article-title":"A user\u2019s guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations","volume":"32","author":"Mollenhauer","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0185-17.2017","DOI":"10.1523\/ENEURO.0185-17.2017","article-title":"The Amyloid Precursor Protein Is a Conserved Receptor for Slit to Mediate Axon Guidance","volume":"4","author":"Wang","year":"2017","journal-title":"eNeuro"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"ref_16","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"ref_17","first-page":"809","article-title":"Molecular markers of Alzheimer disease early diagnostic: Investigation perspectives of peripheral tissues","volume":"30","author":"Paltsev","year":"2017","journal-title":"Adv. Gerontol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ncomms2013","article-title":"Abeta alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo","volume":"3","author":"Cao","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/acn3.629","article-title":"Novel CSF biomarkers to discriminate FTLD and its pathological subtypes","volume":"5","author":"Galimberti","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Karikari","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barthelemy","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification","volume":"12","author":"Barthelemy","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_30","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs. Tau Positron Emission Tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_32","first-page":"313","article-title":"Tau-protein expression in human blood lymphocytes: A promising marker and suitable sample for life-time diagnosis of Alzheimer\u2019s disease","volume":"21","author":"Kvetnoy","year":"2000","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.12703\/r\/10-46","article-title":"Neurofilament light: A narrative review on biomarker utility","volume":"10","author":"Narayanan","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_34","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"870517","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of Anti-amyloid-beta Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer\u2019s Disease: A Focus on Aducanumab and Lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","article-title":"FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns","volume":"613","author":"Reardon","year":"2023","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"q281","DOI":"10.1136\/bmj.q281","article-title":"Aduhelm: Biogen abandons Alzheimer\u2019s drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies","volume":"24","author":"Akcimen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ane.13698","article-title":"Blood biomarkers in ALS: Challenges, applications and novel frontiers","volume":"146","author":"Sturmey","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-022-04436-3","article-title":"TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A","volume":"603","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","article-title":"TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113636","DOI":"10.1016\/j.celrep.2023.113636","article-title":"TDP-43-stratified single-cell proteomic profiling of postmortem human spinal motor neurons reveals protein dynamics in amyotrophic lateral sclerosis","volume":"45","author":"Guise","year":"2024","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41418-020-00664-0","article-title":"ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation","volume":"28","author":"Hor","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41582-023-00891-2","article-title":"Biomarkers in amyotrophic lateral sclerosis: Current status and future prospects","volume":"19","author":"McMackin","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1038\/s41598-020-66090-x","article-title":"Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders","volume":"10","author":"Delaby","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1038\/s41598-021-01499-6","article-title":"Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics","volume":"11","author":"Behzadi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Costa, J., Gromicho, M., Pronto-Laborinho, A., Almeida, C., Gomes, R.A., Guerreiro, A.C.L., Oliva, A., Pinto, S., and de Carvalho, M. (2021). Cerebrospinal Fluid Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11071210"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"712245","DOI":"10.3389\/fneur.2021.712245","article-title":"Role of Blood Neurofilaments in the Prognosis of Amyotrophic Lateral Sclerosis: A Meta-Analysis","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kojima, Y., Kasai, T., Noto, Y.I., Ohmichi, T., Tatebe, H., Kitaoji, T., Tsuji, Y., Kitani-Morii, F., Shinomoto, M., and Allsop, D. (2021). Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260323"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41467-023-37630-6","article-title":"Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology","volume":"14","author":"Ziff","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","article-title":"Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration","volume":"22","author":"Melamed","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","article-title":"ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair","volume":"22","author":"Klim","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","article-title":"A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS","volume":"30","author":"Irwin","year":"2024","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Seddighi, S., Qi, Y.A., Brown, A.L., Wilkins, O.G., Bereda, C., Belair, C., Zhang, Y., Prudencio, M., Keuss, M.J., and Khandeshi, A. (2024). Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS\/FTD. Sci. Transl. Med.","DOI":"10.1101\/2023.01.23.525149"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Xu, A., Luo, Y., Tang, Y., Yang, F., Gao, X., Qiao, G., Zhu, X., and Zhou, J. (2024). Chitinases as a potential diagnostic and prognostic biomarker for amyotrophic lateral sclerosis: A systematic review and meta-analysis. Neurol. Sci.","DOI":"10.1007\/s10072-024-07301-5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/NXI.0000000000000921","article-title":"Chitinases and chitinase-like proteins as biomarkers in neurologic disorders","volume":"8","author":"Pinteac","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnnp-2022-330318","article-title":"Chitinase dysregulation predicts disease aggressiveness in ALS: Insights from the D50 progression model","volume":"94","author":"Gaur","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/jnnp-2019-321916","article-title":"Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes","volume":"91","author":"Vu","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/acn3.51114","article-title":"CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis","volume":"7","author":"Gray","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"fcad287","DOI":"10.1093\/braincomms\/fcad287","article-title":"Urinary biomarkers for amyotrophic lateral sclerosis: Candidates, opportunities and considerations","volume":"5","author":"Rogers","year":"2023","journal-title":"Brain Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","article-title":"Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS","volume":"88","author":"Shepheard","year":"2017","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1007\/s00415-020-10047-7","article-title":"Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"J. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/ene.15237","article-title":"Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis","volume":"29","author":"Shepheard","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/cns.13894","article-title":"Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients","volume":"28","author":"Esselin","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737175.2023.2251687","article-title":"Oral Edaravone\u2014Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis","volume":"23","author":"Pattee","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.27091","article-title":"Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis","volume":"63","author":"Paganoni","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/brain\/awac394","article-title":"Neurofilament light chain in drug development for amyotrophic lateral sclerosis: A critical appraisal","volume":"146","author":"Benatar","year":"2023","journal-title":"Brain"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ana.26371","article-title":"Regulatory Approval in ALS; When Is a Single Study Enough?","volume":"91","author":"Cudkowicz","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41573-023-00083-z","article-title":"NfL makes regulatory debut as neurodegenerative disease biomarker","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","article-title":"Molecular genetics of Parkinson\u2019s disease: Contributions and global trends","volume":"68","author":"Funayama","year":"2023","journal-title":"J. Hum. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and Pathogenesis of Parkinson\u2019s Syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1007\/s00415-022-11282-w","article-title":"Influence of heavy metals in Parkinson\u2019s disease: An overview","volume":"269","author":"Vellingiri","year":"2022","journal-title":"J. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ije\/dyx225","article-title":"Pesticide use in agriculture and Parkinson\u2019s disease in the AGRICAN cohort study","volume":"47","author":"Pouchieu","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.bbadis.2008.08.001","article-title":"Viral parkinsonism","volume":"1792","author":"Jang","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"917499","DOI":"10.3389\/fnagi.2022.917499","article-title":"New Understanding on the Pathophysiology and Treatment of Constipation in Parkinson\u2019s Disease","volume":"14","author":"Xu","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3233\/JPD-161050","article-title":"Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson\u2019s Disease: A Colon Transit and Volume Study","volume":"7","author":"Knudsen","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acschemneuro.2c00730","article-title":"Comprehensive Review on Potential Signaling Pathways Involving the Transfer of alpha-Synuclein from the Gut to the Brain That Leads to Parkinson\u2019s Disease","volume":"14","author":"Kumari","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12964-023-01402-y","article-title":"The involvement of alpha-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson\u2019s disease","volume":"22","author":"Miao","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson\u2019s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural Transm."},{"key":"ref_86","first-page":"2","article-title":"The Search for a Peripheral Biopsy Indicator of alpha-Synuclein Pathology for Parkinson Disease","volume":"76","author":"Lee","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"947191","DOI":"10.3389\/fnmol.2022.947191","article-title":"The relationship of alpha-synuclein to mitochondrial dynamics and quality control","volume":"15","author":"Thorne","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun. Signal"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1523\/JNEUROSCI.4029-08.2009","article-title":"Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum","volume":"29","author":"Matsuda","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/glia.23627","article-title":"Subregional differences in astrocytes underlie selective neurodegeneration or protection in Parkinson\u2019s disease models in culture","volume":"67","author":"Kostuk","year":"2019","journal-title":"Glia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fnagi.2019.00382","article-title":"Ca(V)1.3 L-Type Calcium Channels Increase the Vulnerability of Substantia Nigra Dopaminergic Neurons in MPTP Mouse Model of Parkinson\u2019s Disease","volume":"11","author":"Verma","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_93","unstructured":"Cheslow, L., Byrne, M., Kopenhaver, J.S., Iacovitti, L., Smeyne, R.J., Snook, A.E., and Waldman, S.A. (2023). GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. Res. Sq."},{"key":"ref_94","first-page":"1399","article-title":"Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles","volume":"13","author":"Schule","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/awad260","article-title":"Aggregation and beyond: Alpha-synuclein-based biomarkers in synucleinopathies","volume":"147","author":"Chopra","year":"2024","journal-title":"Brain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using alpha-synuclein seed amplification: A cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e2417","DOI":"10.1212\/WNL.0000000000201199","article-title":"Disease-Associated alpha-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage","volume":"99","author":"Majbour","year":"2022","journal-title":"Neurology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally Derived Extracellular Vesicle alpha-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/mds.28591","article-title":"Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes","volume":"36","author":"Jiang","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ene.14208","article-title":"A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression","volume":"27","author":"Niu","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological alpha-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2018.12.030","article-title":"alpha-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson\u2019s disease","volume":"696","author":"Cao","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin alpha-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41531-023-00519-8","article-title":"Combining skin and olfactory alpha-synuclein seed amplification assays (SAA)-towards biomarker-driven phenotyping in synucleinopathies","volume":"9","author":"Kuzkina","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41531-023-00458-4","article-title":"Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool","volume":"9","author":"Schaffrath","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41531-021-00263-x","article-title":"Enteric alpha-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson\u2019s disease before brain pathology","volume":"8","author":"Pellegrini","year":"2022","journal-title":"NPJ Park. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e100715","DOI":"10.15252\/embj.2018100715","article-title":"Loss of neuronal Miro1 disrupts mitophagy and induces hyperactivation of the integrated stress response","volume":"40","author":"Howden","year":"2021","journal-title":"EMBO J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cmet.2019.08.023","article-title":"Miro1 Marks Parkinson\u2019s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson\u2019s Models","volume":"30","author":"Hsieh","year":"2019","journal-title":"Cell Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"734273","DOI":"10.3389\/fnmol.2021.734273","article-title":"Miro1 Impairment in a Parkinson\u2019s At-Risk Cohort","volume":"14","author":"Nguyen","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12967-023-04493-w","article-title":"Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells","volume":"21","author":"Araya","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3233\/JAD-170613","article-title":"Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer\u2019s Disease","volume":"61","author":"Chai","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: Recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"960314","DOI":"10.3389\/fnagi.2022.960314","article-title":"Inhibiting amyloid beta (1-42) peptide-induced mitochondrial dysfunction prevents the degradation of synaptic proteins in the entorhinal cortex","volume":"14","author":"Olajide","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1089\/ars.2019.7763","article-title":"Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer\u2019s Disease: Targeting Mitochondria for Diagnosis and Prevention","volume":"32","author":"Peng","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"18916","DOI":"10.1038\/s41598-021-97928-7","article-title":"Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated","volume":"11","author":"Singh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1038\/s41598-022-08068-5","article-title":"Mitochondrial dysregulation occurs early in ALS motor cortex with TDP-43 pathology and suggests maintaining NAD(+) balance as a therapeutic strategy","volume":"12","author":"Gautam","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Smith, L., and Schapira, A.H.V. (2022). GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 11.","DOI":"10.3390\/cells11081261"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","article-title":"Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI","volume":"7","author":"Huh","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/mds.28472","article-title":"The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PD(GBA)","volume":"36","author":"Lerche","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.29360","article-title":"A Biomarker Study in Patients with GBA1-Parkinson\u2019s Disease and Healthy Controls","volume":"38","author":"Cullen","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1212\/WNL.0000000000009989","article-title":"beta-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters","volume":"95","author":"Huh","year":"2020","journal-title":"Neurology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11064-021-03411-0","article-title":"Fecal Microbiota Transplantation Exerts a Protective Role in MPTP-Induced Parkinson\u2019s Disease via the TLR4\/PI3K\/AKT\/NF-kappaB Pathway Stimulated by alpha-Synuclein","volume":"46","author":"Zhong","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41531-021-00244-0","article-title":"Association between Parkinson\u2019s disease and the faecal eukaryotic microbiota","volume":"7","author":"Weis","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.26719","article-title":"Metagenomics of the Gut Microbiome in Parkinson\u2019s Disease: Prodromal Changes","volume":"94","author":"Palacios","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","article-title":"Initiation of pharmacological therapy in Parkinson\u2019s disease: When, why, and how","volume":"19","author":"Clarke","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: Etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mds.29318","article-title":"Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein","volume":"38","author":"Jensen","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_131","first-page":"25","article-title":"Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer\u2019s and Parkinson\u2019s Patients","volume":"10","author":"Fang","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","article-title":"Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation","volume":"20","author":"Kuai","year":"2021","journal-title":"Microb. Cell Fact."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/4\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:46Z","timestamp":1760105926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/4\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":132,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["biom14040398"],"URL":"https:\/\/doi.org\/10.3390\/biom14040398","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}